Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors

Core Insights - Mineralys Therapeutics has appointed Dr. Alexander M. Gold to its Board of Directors, effective June 13, 2024, to support the late-stage clinical development of lorundrostat for hypertension and related cardiorenal metabolic disorders [1][5][10] - Dr. Gold brings over 20 years of experience in biopharmaceuticals, having held executive roles in various companies and currently serving as Chief Medical Officer at a clinical-stage biotech firm [6][10] - The company also announced the resignation of Olivier Litzka from the Board, expressing gratitude for his contributions [3][10] Company Overview - Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for hypertension, chronic kidney disease (CKD), and other diseases linked to dysregulated aldosterone [12] - The primary product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor designed to treat uncontrolled hypertension and CKD [7][12] Product Development - Lorundrostat has shown a 70% reduction in plasma aldosterone concentration in hypertensive subjects and has a selectivity of 374-fold for aldosterone-synthase inhibition compared to cortisol-synthase inhibition [7] - In a Phase 2 trial, lorundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontrolled hypertension [11]